A hypoxia risk score for prognosis prediction and tumor microenvironment in adrenocortical carcinoma

• Published in: Frontiers in genetics Vol. 13; p. 796681
• Main Authors: Deng, Yuanyuan, Li, Huihuang, Fu, Jinglan, Pu, Ying, Zhang, Ying, Chen, Shijing, Tong, Shiyu, Liu, Huixia
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 13.12.2022
• Subjects: Adrenocortical carcinoma; Genetics; hypoxia; immunotherapy; risk score; tumor microenvironment; hypoxia; tumor microenvironment; Adrenocortical carcinoma; immunotherapy; risk score
• ISSN: 1664-8021; 1664-8021
• DOI: 10.3389/fgene.2022.796681

Adrenocortical carcinoma (ACC) is a rare malignant endocrine tumor derived from the adrenal cortex. Because of its highly aggressive nature, the prognosis of patients with adrenocortical carcinoma is not impressive. Hypoxia exists in the vast majority of solid tumors and contributes to invasion, metastasis, and drug resistance. This study aimed to reveal the role of hypoxia in Adrenocortical carcinoma and develop a hypoxia risk score (HRS) for Adrenocortical carcinoma prognostic prediction. Hypoxia-related genes were obtained from the Molecular Signatures Database. The training cohorts of patients with adrenocortical carcinoma were downloaded from The Cancer Genome Atlas, while another three validation cohorts with comprehensive survival data were collected from the Gene Expression Omnibus. In addition, we constructed a hypoxia classifier using a random survival forest model. Moreover, we explored the relationship between the hypoxia risk score and immunophenotype in adrenocortical carcinoma to evaluate the efficacy of immune check inhibitors (ICI) therapy and prognosis of patients. HRS and tumor stage were identified as independent prognostic factors. HRS was negatively correlated with immune cycle activity, immune cell infiltration, and the T cell inflammatory score. Therefore, we considered the low hypoxia risk score group as the inflammatory immunophenotype, whereas the high HRS group was a non-inflammatory immunophenotype. In addition, the HRS was negatively related to the expression of common immune checkpoint molecules such as PD-L1, CD200, CTLA-4, and TIGIT, suggesting that patients with a lower hypoxia risk score respond better to immunotherapy. We developed and validated a novel hypoxia risk score to predict the immunophenotype and response of patients with adrenocortical carcinoma to immune check inhibitors therapy. These findings not only provide fresh prognostic indicators for adrenocortical carcinoma but also offer several promising treatment targets for this disease.